Day: January 27, 2026

Vancouver B.C., Jan. 27, 2026 (GLOBE NEWSWIRE) — TERRA CLEAN ENERGY CORP. (“Terra” or the “Company”) (CSE: TCEC, OTCQB: TCEFF, FSE: C9O0) welcomes the recent announcement by Governor Cox of Utah unveiling “Mission Critical” a mine-to-market state strategy for critical minerals, built with clarity, speed, and responsibility.  The state plans to approve five mining projects in 2026 and to bring a national lab to Utah by 2031 making Utah the No. 1 destination for critical mineral extraction and processing in the United States. In late 2025, uranium was added to the U.S. Government’s list of critical minerals deeming it vital to the U.S. economy.  Being on the critical minerals list can influence federal as well as state policy in several ways including: Fast track permittingDomestic mining and processing incentivesPrioritization...

Engagement of Xcalibur Smart Mapping to Accelerate Exploration Momentum Following Successful Public Listing VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) — One Bullion Ltd. (“One Bullion” or the “Company”) (TSXV: OBUL), a gold exploration company holding complete ownership of three highly prospective mining areas in Botswana, is pleased to announce that it has engaged Xcalibur Smart Mapping to conduct a comprehensive high resolution Airborne Magnetic Gradiometer and Radiometrics survey over both Vumba and Maitengwe projects, in the North-East and Central Districts of Botswana, respectively. The planned surveys represent a key milestone as the Company advances toward drill-ready targets in its 2026 exploration program. “These surveys are a critical step in systematically unlocking value across our portfolio and positioning...

PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food and Drug Administration (FDA) on January 21, 2026. The objective of this meeting was to review plans for the proposed Phase 2b study of zervimesine in dementia with Lewy bodies (DLB), a disease with no FDA-approved therapies. “We had a productive meeting with the FDA, during which we discussed clinically meaningful endpoints for the next Phase 2b study of mild-to-moderate DLB,” stated Anthony O. Caggiano, MD, PhD, Cognition’s chief medical officer. “We look forward to receiving meeting minutes later this quarter and continuing our dialogue with the FDA to advance clinical development...

Order highlights continued strong demand for Gilat’s GEO and LEO compatible Electronically Steered Antenna technology PETAH TIKVA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced that its Commercial Division received a multimillion order from a large global avionics company for the supply of Sidewinder electronically steered antenna terminals designed by Gilat Stellar Blu. Deliveries are expected within the next 6 months. The order reflects continued momentum for Gilat’s Sidewinder ESA platform and growing demand for advanced inflight connectivity solutions that combine high performance with a low profile, lightweight configuration. Sidewinder ESA is designed for commercial, business,...

        Company Announcement No 03/2026Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37 AL Sydbank A/SCVR No DK 12626509, Aabenraasydbank.com27 January 2026  Dear Sirs Change of share capital At the ekstraordinay general meeting of Sydbank A/S held on 4 December 2025 it was resolved to reduce the Bank’s share capital by nominally DKK 21,737,530 by cancelling 2,173,753 shares. The creditors’ time limit for filing claims has expired and the Board ofDirectors has subsequently decided to implement the capital reduction. The capital reduction will be registered with the Danish BusinessAuthority. AL Sydbank’s total share capital represents nominally DKK 857,884,160,equal to 85,788,416 shares of DKK 10 each (85,788,416 voting rights). As a result of the capital reduction the Bank’s Articles of Association havebeen amended with...

– Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – – Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – – Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naïve patients, as published in the Journal of Clinical Oncology – – Onvansertib continues to be safe and well-tolerated – – Company expects to provide final data and registrational plans in first half of 2026 – – Company to hold conference call today at 8:30 a.m. ET/5:30 a.m. PT – SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) — Cardiff...